OBJECTIVE: Investigate the clinical landscape of ovarian carcinoma(OC) over time. DESIGN: Register-based prospectively collected data. SETTING: South-East Scotland SAMPLE: 2805 OC patients diagnosed 1981-2015. METHODS: Survival times were visualised using the Kaplan-Meier method; median survival, 5-year survival probabilities and associated restricted mean survival time analyses were used to quantify survival differences MAIN OUTCOME MEASURES: Disease-specific survival. RESULTS: Significant increase in disease-specific survival(DSS) from 1981-1985 to 2011-2015 was observed (median 1.73 vs 4.23 years, p<0.0001). Corresponding increase in progression-free survival(PFS) was not statistically significant (median 1.22 vs 1.58 years, p=0.2568). An increase in the proportion of cases with low residual disease volume (RD) (<2cm RD) following debulking was observed (54.0% vs 87.7%, p<0.0001). The proportion of high grade serous (HGS) cases increased (p<0.0001), while endometrioid and mucinous cases decreased (p=0.0005 and p=0.0002). Increases in stage IV HGSOC incidence (p=0.0009) and stage IV HGSOC DSS (p=0.0122) were observed. Increasing median age at diagnosis correlated with increasing Eastern Cooperative Oncology Group Performance Status (ECOG PS) over time (r=0.86). CONCLUSIONS: OC DSS has improved over the last 35 years; PFS has not significantly increased, highlighting that improvement in outcome has been limited to extending post-relapse survival. Distribution of stage at diagnosis, histological subtype and RD following debulking have changed over time, reflecting evolution in tumour classification, staging and optimal debulking definitions (from low RD to minimal or zero RD). Histology, stage, RD and ECOG PS remain reliable outcome predictors. Increasing median age at diagnosis and ECOG PS indicates demographic shifts in the clinical population. This article is protected by copyright. All rights reserved.
OBJECTIVE: Investigate the clinical landscape of ovarian carcinoma(OC) over time. DESIGN: Register-based prospectively collected data. SETTING: South-East Scotland SAMPLE: 2805 OC patients diagnosed 1981-2015. METHODS: Survival times were visualised using the Kaplan-Meier method; median survival, 5-year survival probabilities and associated restricted mean survival time analyses were used to quantify survival differences MAIN OUTCOME MEASURES: Disease-specific survival. RESULTS: Significant increase in disease-specific survival(DSS) from 1981-1985 to 2011-2015 was observed (median 1.73 vs 4.23 years, p<0.0001). Corresponding increase in progression-free survival(PFS) was not statistically significant (median 1.22 vs 1.58 years, p=0.2568). An increase in the proportion of cases with low residual disease volume (RD) (<2cm RD) following debulking was observed (54.0% vs 87.7%, p<0.0001). The proportion of high grade serous (HGS) cases increased (p<0.0001), while endometrioid and mucinous cases decreased (p=0.0005 and p=0.0002). Increases in stage IV HGSOC incidence (p=0.0009) and stage IV HGSOC DSS (p=0.0122) were observed. Increasing median age at diagnosis correlated with increasing Eastern Cooperative Oncology Group Performance Status (ECOG PS) over time (r=0.86). CONCLUSIONS: OC DSS has improved over the last 35 years; PFS has not significantly increased, highlighting that improvement in outcome has been limited to extending post-relapse survival. Distribution of stage at diagnosis, histological subtype and RD following debulking have changed over time, reflecting evolution in tumour classification, staging and optimal debulking definitions (from low RD to minimal or zero RD). Histology, stage, RD and ECOG PS remain reliable outcome predictors. Increasing median age at diagnosis and ECOG PS indicates demographic shifts in the clinical population. This article is protected by copyright. All rights reserved.
Authors: Patricia Roxburgh; Charlie Gourley; Colin A Semple; Ailith Ewing; Alison Meynert; Michael Churchman; Graeme R Grimes; Robert L Hollis; C Simon Herrington; Tzyvia Rye; Clare Bartos; Ian Croy; Michelle Ferguson; Mairi Lennie; Trevor McGoldrick; Neil McPhail; Nadeem Siddiqui; Suzanne Dowson; Rosalind Glasspool; Melanie Mackean; Fiona Nussey; Brian McDade; Darren Ennis; Lynn McMahon; Athena Matakidou; Brian Dougherty; Ruth March; J Carl Barrett; Iain A McNeish; Andrew V Biankin Journal: Clin Cancer Res Date: 2021-03-19 Impact factor: 12.531
Authors: Kelly L Bolton; Francesmary Modugno; Ellen L Goode; Julie M Cunningham; Stacey J Winham; Chen Wang; Britta Weiglt; Zhuxuan Fu; Sebastian M Armasu; Bryan M McCauley; Alison H Brand; Yoke-Eng Chiew; Esther Elishaev; Charlie Gourley; Catherine J Kennedy; Angela Laslavic; Jenny Lester; Anna Piskorz; Magdalena Sekowska; James D Brenton; Michael Churchman; Anna DeFazio; Ronny Drapkin; Kevin M Elias; David G Huntsman; Beth Y Karlan; Martin Köbel; Jason Konner; Kate Lawrenson; Elli Papaemmanuil Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-10-25 Impact factor: 4.090
Authors: Robert L Hollis; Ian Croy; Michael Churchman; Clare Bartos; Tzyvia Rye; Charlie Gourley; C Simon Herrington Journal: Br J Cancer Date: 2022-06-17 Impact factor: 9.075
Authors: Charlie Gourley; C Simon Herrington; Robert L Hollis; Barbara Stanley; John P Thomson; Michael Churchman; Ian Croy; Tzyvia Rye; Clare Bartos; Fiona Nussey; Melanie Mackean; Alison M Meynert; Colin A Semple Journal: NPJ Precis Oncol Date: 2021-06-02
Authors: Robert L Hollis; John P Thomson; Barbara Stanley; Michael Churchman; Alison M Meynert; Tzyvia Rye; Clare Bartos; Yasushi Iida; Ian Croy; Melanie Mackean; Fiona Nussey; Aikou Okamoto; Colin A Semple; Charlie Gourley; C Simon Herrington Journal: Nat Commun Date: 2020-10-05 Impact factor: 14.919